Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone (NCT07381543) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone
China76 participantsStarted 2026-03
Plain-language summary
Observation and Evaluation of the Efficacy and Safety of Adalimumab Combined with Chemotherapy Followed by Radiotherapy or Radiotherapy Alone as First-Line Treatment for Limited-Stage Small Cell Lung Cancer
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age: 18-75 years old, male or female;
✓. Patients with pathologically confirmed localized small cell lung cancer (as defined by the Veterans Administration Lung Study Group, VALG staging);
✓. No anticipated need for tumor resection during the study period (including patients unsuitable for surgery or unwilling to undergo surgery);
✓. No prior treatment for localized small cell lung cancer;
✕. History of other malignancies within the past 5 years or concurrent malignancies, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial or non-invasive bladder cancer;
✕. History of uncontrollable psychiatric disorders or severe intellectual or cognitive impairment;
✕. Active, known, or suspected autoimmune disease; however, subjects with hypothyroidism requiring only hormone replacement therapy or skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are eligible;
What they're measuring
1
PFS
Timeframe: through study completion, an average of 3 years
Trial details
NCT IDNCT07381543
SponsorPeking University Cancer Hospital & Institute
✕. Subjects with any severe and/or uncontrolled medical conditions, including:
✕. Subjects with uncontrolled blood pressure (systolic ≥150 mmHg or diastolic ≥100 mmHg);
✕. Subjects with ≥ Grade 2 myocardial ischemia or myocardial infarction, arrhythmias (including male QTc ≥ 450 ms or female QTc ≥ 470 ms), and ≥ Grade 2 congestive heart failure (New York Heart Association \[NYHA\] classification);